Workflow
创新产品拓展
icon
Search documents
国金证券给予健帆生物买入评级,渠道管理导致短期承压,创新产品快速拓展
Mei Ri Jing Ji Xin Wen· 2025-08-22 02:13
Group 1 - The core viewpoint of the report is that Jianfan Biological (300529.SZ) is rated as a "buy" due to its potential for long-term profitability despite short-term performance pressures [2] - The company is strengthening channel management, which may lead to short-term performance challenges [2] - Rapid expansion of new product lines is expected to enhance long-term profitability [2]